Graeme F. Woodworth, MD

Dr. Woodworth brings more than 20 years of experience as a neurosurgeon and clinician-scientist specializing in brain tumor therapy, image-guided neurosurgery, and nanoparticle-based drug delivery. He serves as Chair of the Department of Neurosurgery and Director of the Brain Tumor Program at the University of Maryland School of Medicine, where his research focuses on therapeutic delivery across the blood-brain barrier and targeted approaches for malignant gliomas.

As a scientific advisor and one of the inventors of the NOVVA™ platform, Dr. Woodworth provides critical insight into the translational and clinical development of Lumigen’s targeted nanoparticle therapeutics. His expertise as a neurosurgeon is instrumental in guiding the company’s LUM-001 program for glioblastoma, ensuring alignment between preclinical innovation and clinical feasibility.

Dr. Woodworth earned his BS in Chemistry from Tufts University and his MD from Johns Hopkins University School of Medicine. He completed fellowships in neuro-oncology, nanotechnology, and cranial endoscopy, and has led pioneering clinical research in MRI-guided focused ultrasound for blood-brain barrier modulation.